RPG Life Sciences Ltd.

2,216.7

17.1 (0.8%)stock indicator image for upward trend

As on June 12, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap3,653 Cr
P/E Ratio20.01
Dividend Yield0.14 %
Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

This image for unlock stock of the monthUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open2,204.9
High2,308.8
NSE SymbolRPGLIFE
Close2,216.7
Low2,188.2
BSE Symbol532983
Previous Years High/Low
1 Year High2,725
3 Year High2,974.95
5 Year High2,974.95
1 Year Low1,733
3 Year Low876.1
5 Year Low431.15

Technicals


IndicatorsValueSignal
5-DMA2,146.12Bullish
10-DMA2,161.46Bullish
20-DMA2,214.16Bullish
50-DMA2,139.59Bullish
100-DMA2,055.07Bullish
200-DMA2,192.11Bullish

Historical Performance


1 Year
-1.3%
3 Years
139.4%
5 Years
375.4%
10 Years
820.4%

Shareholding Pattern


%

Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


Compounded Sales Growth
10 Years:N/A
5 Years:N/A
3 Years:N/A
TTM:N/A
Compounded Profit Growth
10 Years:N/A
5 Years:N/A
3 Years:N/A
TTM:N/A
Stock Price CAGR
10 Years:24.9
5 Years:36.1
3 Years:34.9
TTM:-5.3
Return on Equity
10 Years:N/A
5 Years:N/A
3 Years:N/A
last year:N/A

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a moderate PE of 20.01, suggesting fair valuation relative to earnings.
  • Over the last three years, the stock delivered a strong 3-year price CAGR of 34.9%, indicating sustained price appreciation.
  • The stock carries a beta of 0.8, indicating volatility broadly in line with the market.
  • In the last financial year, the company reported an EBITDA of ₹1733 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹6534 million, suggesting a mid-sized operation.

Investment Calculator


Investment Amount: ₹ 1000000
Current Value: ₹ 923894.5
No. of Shares: 417 (Approx)
Performance:-7.6%
P/L: ₹-76105.5
NIFTY Performance: -4.4%
1 day Top Gainers
SymbolChange%
IFCI84.57(20%)
AIIL530.15(15%)
TTML46.44(10%)
ASHOKLEY152.45(10%)
NETWEB4587.4(9%)
1 Day Top Losers
SymbolChange%
NESTLEIND1375.7(-3%)
OIL417.8(-3%)
ONGC246.2(-3%)
TECHM1429.2(-3%)
ONESOURCE1612.5(-2%)
INOXINDIA1808.2(-2%)
PREMIERENE1034.6(-2%)
IPCALAB1583(-2%)

Top Performing Stocks from the same sector


Venus Remedies Ltd.

92.9%

1797.5

1 Month Performance

Bliss GVS Pharma Ltd.

59.9%

437.85

1 Month Performance

Panacea Biotec Ltd.

46.6%

536

1 Month Performance

Sakar Healthcare Ltd.

44.7%

824.1

1 Month Performance

Supriya Lifescience Ltd.

44.6%

977.15

1 Month Performance

Rubicon Research Ltd.

39.6%

1295.5

1 Month Performance

NGL Fine-Chem Ltd.

39.3%

3048.8

1 Month Performance

Senores Pharmaceuticals Ltd.

38.3%

1290

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month